TRBC1-Targeting Antibody–Drug Conjugates for the Treatment of T Cell Cancers

2025-04-08T15:34:44-04:00July 3rd, 2024|Case Studies|

To develop robust mAb biologics, it is vital to fully characterize the protein, including its primary sequence, mutations, and important post-translational modifications